BeOne Medicines is an oncology company which involved in discovering and developing treatments to cancer patients. BeOne Medicines, formerly known as BeiGene Ltd., is based in SAN CARLOS, Calif.
| Revenue (Most Recent Fiscal Year) | $3.81B |
| Net Income (Most Recent Fiscal Year) | $-644.79M |
| PE Ratio (Current Year Earnings Estimate) | 97.79 |
| PE Ratio (Trailing 12 Months) | 196.43 |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 8.05 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 8.97 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | 3.67% |
| Net Margin (Trailing 12 Months) | 1.38% |
| Return on Equity (Trailing 12 Months) | 5.52% |
| Return on Assets (Trailing 12 Months) | 3.17% |
| Current Ratio (Most Recent Fiscal Quarter) | 2.39 |
| Quick Ratio (Most Recent Fiscal Quarter) | 2.17 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.03 |
| Inventory Turnover (Trailing 12 Months) | 1.36 |
| Book Value per Share (Most Recent Fiscal Quarter) | $34.10 |
| Earnings per Share (Most Recent Fiscal Quarter) | $1.09 |
| Earnings per Share (Most Recent Fiscal Year) | $-6.12 |
| Diluted Earnings per Share (Trailing 12 Months) | $0.51 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 118.54M |
| Free Float | 110.69M |
| Market Capitalization | $40.05B |
| Average Volume (Last 20 Days) | 0.31M |
| Beta (Past 60 Months) | 0.45 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 6.62% |
| Percentage Held By Institutions (Latest 13F Reports) | 48.55% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |